HVEM, LIGHT & BTLA: New Immunotherapy Target
The checkpoint receptors HVEM , LIGHT , CD160 , and BTLA are part of a complex network of overlapping receptor interactions that function in both immune stimulation and suppression 1 , 2 . This regulatory function has made them therapeutic targets for treatment of cancer, autoimmune diseases and allergies, and for improved methods of organ transplants. While presenting opportunities for...
BTLA Screening Services
B and T Lymphocyte Attenuator, or BTLA, is a human protein which inhibits T cell activation. BTLA is expressed by cytotoxic T cells (CTL), which are T lymphocytes that are able to kill foreign pathogens, viral-infected cells, and cancer cells. BTLA binding to its ligand, herpesvirus entry mediator (HVEM), results in inhibition of CTL activation. Certain cancers are able to evade the immune system by taking advantage of this inhibitory pathway.
In th...
Combining Therapies for Targeting Immune Checkpoints
| IMMUNE CHECKPOINTS | | KINASES | | PARPS | | HDACS | | CAR T-CELL THERAPY |
Cancer is a balance between the defens...
Immunotherapy Biochemical Screening Services
Immunotherapy is a type of medical treatment that engages the body's immune system to fight diseases, such as cancer, infections, and autoimmune disorders. It works by either stimulating the immune system to attack cancer cells or other disease-causing agents, or by using synthetic proteins or antibodies to target specific molecules on the surface of cancer cells or other pathogens. Immunotherapy has shown prom...
